CELMoDs are being actively trialed as a maintenance therapy after CAR T-cell treatment. The strategy is to leverage the CELMoDs' ability to enhance T-cell function and upregulate effector T-cells to boost the activity and persistence of the CAR-T product, potentially leading to more durable responses and preventing relapse.

While specialized centers handle acute CAR-T toxicities like CRS and ICANS, the most life-threatening long-term side effect is infection. This shifts the primary responsibility of care to community hematologists and oncologists, who must proactively manage this risk with patients after they are discharged.

Unlike stem cell transplants, CAR T-cell therapy has less intense conditioning, making it a viable option for patients into their late 80s. Eligibility focuses more on fitness and frailty rather than chronological age, broadening access for a larger patient population.

Experts now view a patient's response to bridging therapy as a key predictor of CAR T outcomes. A patient who fails to respond or progresses during bridging has a much higher risk of toxicity and poor efficacy and should be considered for alternative treatments.

Despite exciting early efficacy data for in vivo CAR-T therapies, the modality's future hinges on the critical unanswered question of durability. How long the therapeutic effects last, for which there is little data, will ultimately determine its clinical viability and applications in cancer versus autoimmune diseases.

It's a myth that patients must have active disease to receive their manufactured CAR-T cells. Data from the TRANSFORM study shows that patients who achieved a complete response with bridging therapy while awaiting cell manufacturing still proceeded with the infusion and benefited.

The efficacy of Siltacel stems from a powerful initial expansion that eliminates cancer upfront. The CAR-T cells are often undetectable beyond six months, indicating their curative potential comes from an overwhelming initial response rather than persistent, long-term immune policing of the disease.

The next major shift for CAR T-cell therapy is its integration into frontline treatment. Instead of being reserved for relapse, it's being tested as a consolidation therapy that could replace the standard two to three years of maintenance chemotherapy, dramatically shortening treatment duration.

Current CAR-T therapy for CLL requires a complete response (CR) for long-term benefit. A partial response provides only about two years of disease control, an outcome similar to the oral drug pirtobrutinib but with significantly more toxicity, complexity, and logistical burden for the patient.